Skip to main content
. Author manuscript; available in PMC: 2018 Nov 28.
Published in final edited form as: J Control Release. 2017 Sep 20;266:129–139. doi: 10.1016/j.jconrel.2017.09.024

Figure 4. Post-treatment analysis of drug response of breast cancer cells on T-MOC platform.

Figure 4

(A) Time-lapse fluorescence micrographs of cellular drug uptake and cell-type specific response. (B) Post-treatment survival fraction of breast cancer cells cultured on T-MOC and 2D conditions. Results reported in terms of mean ± standard error. Both cell lines became significantly more resistant to Dox on T-MOC, compared to 2D culture (p-value < 0.05). While the two cell lines showed similar levels of resistance to Dox in 2D culture, MDA-MB-231 became significantly more resistant than MCF-7 on T-MOC (p-value < 0.05). (C) Western-blot of doxorubicin resistance-associated proteins of breast cancer cells cultured on T-MOC and 2D conditions as well as in vivo tumor xenograft model.